Searched for
BIOLOGICS INC
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- Early Anthropic backer Menlo lands $3 billion in its largest-ever haulMenlo is set to announce that it’s raised $3 billion for a set of funds dedicated to backing AI startups, marking the venture firm’s larges...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
- Meta AI chief sees opportunity in models’ giving health adviceThe 29-year-old founder of data-labeling startup Scale AI joined Meta after Chief Executive Officer Mark Zuckerberg overhauled his company’...
- Samsung’s $416,000 chip worker bonuses may reshape labour battles in South KoreaSamsung Electronics has agreed to a significant bonus deal with its union, a move that could reshape wage bargaining in South Korea. Memory...
- H-1B chill sets in; Flipkart doubles down on ShopsyUS demand for H-1B visas has slumped to a seven-year low amid steeper costs and Trump-era policy shifts. This and more in today’s ETtech To...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive CapitalAI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of t...
- Quote of the Day by Steve Jobs, “If you really look closely, most overnight successes took a....” Success lesson by the man who turned repeated failure into global success: Steve Jobs reveals the brutal truth behind “overnight success”—are you making this costly mistake of quitting too early today?Steve Jobs quote reveals harsh truth: are you quitting too early before success compounds after years of hidden effort? Overnight success i...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Biocon Biologics expands collaboration with Civica to supply affordable insulin in USBiocon Biologics is expanding its partnership with Civica. This new agreement will bring affordable Insulin Glargine to patients in the Uni...
- Biocon Biologics settles patent issue; paves way for launch of biosimilar product in CanadaBiocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalm...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Biocon Biologics takes over Viatris' biosimilar biz in over 70 countriesBiocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countr...
Load More
